**Gene Tested:**  GLA

**Also Known As:**
- Alpha-Galactosidase A Deficiency (GLA Deficiency)
- Anderson-Fabry Disease

**Disorder:** Fabry disease is a lysosomal storage disease caused by decreased activity of alpha-galactosidase A. Fabry disease is inherited as an X-linked dominant disorder and affects about 1 in 40,000 males in all ethnic groups. Heterozygous (carrier) females may be symptomatic although the incidence of Fabry disease in females is not well ascertained.

Males typically present in childhood with hand pain, temperature intolerance, and unexplained high fevers. Around puberty, males may develop flat or slightly raised vascular lesions, abdominal pain, nausea, diarrhea, and absence of sweating or diminished sweating. Life-threatening complications of kidney failure, heart disease, and strokes may present as early as the third to fourth decade. Without any medical intervention, males with Fabry disease typically die in their mid forties. Modern medical interventions, such as kidney transplant and enzyme replacement therapy, may extend the lives of affected males. Heterozygous females may be completely asymptomatic or as severely affected as males. The majority of heterozygous women have a combination of signs and symptoms that present later than those in affected males. However, women remain at increased risk for kidney failure, heart disease, and early strokes.

In males, the diagnosis of Fabry disease is confirmed by measuring decreased GLA enzyme activity in plasma, leukocytes or cultured skin fibroblasts. Enzyme testing is unreliable in females. Molecular determination of the specific GLA mutation is recommended in all patients and is essential for accurate carrier testing in at-risk females.

**Indications:**
- Confirmation of diagnosis in a symptomatic individual
- Presymptomatic testing of at-risk relatives
- Carrier identification in individuals with a family history of Fabry disease
- Prenatal diagnosis of an at-risk fetus, after confirmation of mutation in the mother or sibling (by prior arrangement only)

**Specimen:**
Blood samples should be collected in EDTA (lavender topped) tubes. A minimum of 5 mLs on adult or 3 mLs on child is required for analysis. Blood collected on Friday may be stored in refrigerator until Monday for overnight shipment.

For other tissue requirements please call 1-800-344-2462, extension 4474.

**Testing Methodology:** PCR-based sequencing of all seven exons and exon/intron boundaries of the GLA gene.

**Test Sensitivity:**
PCR-based sequencing of the GLA gene identifies a mutation in >99% of male patients with Fabry disease. The sensitivity of DNA sequencing is over 99% for the detection of nucleotide base changes, as well as small deletions and insertions in the regions analyzed. Multiple exon deletions and insertions may not be identified by this methodology but are rare in Fabry disease. GLA is the only gene associated with Fabry disease.

**Turn-Around Time:** Reports are routinely available within 21 days of sample receipt. Abnormal results will be called to the referring physician. All reports will be faxed to the referring physician.
**CPT Codes:**
- GLA Full Gene Sequencing 81405
- Family Mutation Studies 81403

Please call 1-866-450-4198 for pricing, insurance preauthorization, or with any billing questions.

**Results:** Each test report includes a detailed interpretation of the genetic findings, the clinical significance of the result, and specific recommendations for clinical management and additional testing, if warranted. Results will be reported to the referring physician or health care provider as specified on the test requisition form.

Additional information and test requisitions are available at: www.cchmc.org/molecular-genetics

**Shipping Instructions:**
Please enclose **test requisition** with sample. **All information must be completed before sample can be processed.**

Place samples in styrofoam mailer and ship at room temperature by overnight Federal Express to arrive Monday through Friday

**Ship to:**
Cytogenetics and Molecular Genetics Laboratories
3333 Burnet Avenue NRB 1042
Cincinnati, OH 45229
513-636-4474